Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2010 by National Cancer Institute (NCI).
Recruitment status was:  Recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: April 7, 2010
Last updated: August 23, 2013
Last verified: April 2010

RATIONALE: Drugs used in chemotherapy, such as liposome-encapsulated doxorubicin citrate and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether liposome-encapsulated doxorubicin citrate is more effective when given together with or without gemcitabine hydrochloride in killing tumor cells.

PURPOSE: This randomized phase II trial is studying liposome-encapsulated doxorubicin citrate given together with gemcitabine hydrochloride to see how well it works compared with liposome-encapsulated doxorubicin citrate alone in treating patients with ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancer.

Condition Intervention Phase
Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer
Drug: gemcitabine hydrochloride
Drug: liposome-encapsulated doxorubicin citrate
Procedure: quality-of-life assessment
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment
Official Title: Randomized Phase II AGO-Study Comparing Combined Liposomal Doxorubicin (Myocet) and Gemcitabine (Gemzar) With Liposomal Doxorubicin (Myocet) Monotherapy in Platinum-Refractory and Platinum-Resistant Epithelial Cancer of the Ovary, Fallopian Tube and the Peritoneum

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Remission rates (complete response and partial response)

Secondary Outcome Measures:
  • Quality of life as measured by EORTC-QLQ30 and QLQ-OV28 questionnaires
  • Progression-free survival
  • Overall survival
  • Toxicity

Estimated Enrollment: 154
Study Start Date: July 2009
Estimated Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Detailed Description:



  • To assess the response rate to liposome-encapsulated doxorubicin citrate and gemcitabine hydrochloride versus liposome-encapsulated doxorubicin citrate alone in patients with platinum-refractory or platinum-resistant ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer.


  • To assess the quality of life of patients treated with these regimens.
  • To determine the progression-free and overall survival of patients treated with these regimens.
  • To determine the toxicity of these regimens.

OUTLINE: This is a multicenter study. Patients are stratified according to disease (platinum-refractory disease vs platinum-resistant disease. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive liposome-encapsulated doxorubicin citrate IV over 60 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive liposome-encapsulated doxorubicin citrate IV over 60 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

Patients who experience clinical benefit after completion of 6 courses of chemotherapy may continue therapy at the discretion of the investigator.

Patients complete quality-of-life questionnaires (EORTC-QLQ30 and QLQ-OV28) at baseline, during, and after completion of study therapy. After completion of study treatment, patients are followed up every 3 months for up to 1 year.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer
  • Progression or recurrence during first-line platinum-based chemotherapy (platinum-refractory disease) OR progression or recurrence during the first 6 months following the end of the last platinum-containing chemotherapy (platinum-resistant disease)
  • Meets ≥ 1 of the following criteria:

    • Measurable metastatic disease on CT or MRI scan, ultrasound, or chest x-ray
    • Evaluable disease on CT/MRI scan (e.g., ascites or pleural effusion) or chest x-ray (e.g., pleural effusion)
    • Tumor marker progression (CA-125) according to Rustin criteria, meeting 1 of the following criteria:

      • CA-125 > 2 times upper limit of normal (UNL)
      • CA-125 > 2 times nadir value on two occasions
  • No ovarian carcinosarcoma (malignant mixed Müllerian tumor) or pure sarcoma


  • Karnofsky performance status 70-100%
  • Life expectancy ≥ 3 months
  • Platelet count ≥ 100,000/mm³
  • Hemoglobin ≥ 10 g/dL
  • Neutrophil count ≥ 1.5 x 10³/mm³
  • Serum creatinine < 1.5 times ULN
  • Bilirubin < 1.5 times ULN (< 2.5 times ULN if liver metastases are present)
  • AST/ALT < 2.5 times ULN (unless caused by parenchymal liver metastases)
  • No childbearing capacity
  • LVEF ≥ 50% by ECHO or MUGA scan
  • No significant comorbidity (e.g., uncontrolled infection, clinical signs of cardiac insufficiency, history of myocardial infarction, or cardiac rhythmic disorders [NYHA class III-IV disease])
  • No known hypersensitivity to study drugs
  • No active secondary malignant tumor within the past 5 years (e.g., metastases from primary breast cancer)
  • No condition (medical, social, or psychological), that would prevent adequate follow-up


  • No prior chemotherapy with pegylated liposomal doxorubicin hydrochloride, other anthracyclines, or gemcitabine hydrochloride
  • No other concurrent tumor-specific therapy for ovarian cancer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01100372

Innsbruck Universitaetsklinik Recruiting
Innsbruck, Austria, A-6020
Contact: Contact Person    43-512-504-24155   
Sponsors and Collaborators
Medical University Innsbruck
Principal Investigator: Alain Zeimet Medical University Innsbruck
  More Information Identifier: NCT01100372     History of Changes
Other Study ID Numbers: CDR0000669716
Study First Received: April 7, 2010
Last Updated: August 23, 2013

Keywords provided by National Cancer Institute (NCI):
recurrent ovarian epithelial cancer
recurrent fallopian tube cancer
recurrent primary peritoneal cavity cancer

Additional relevant MeSH terms:
Fallopian Tube Neoplasms
Peritoneal Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Fallopian Tube Diseases
Adnexal Diseases
Genital Diseases, Female
Abdominal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Peritoneal Diseases
Liposomal doxorubicin
Citric Acid
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors processed this record on May 22, 2017